title: Prognostic factors and expression of MDM2 in patients with primary extremity liposarcoma.
abstract: OBJECTIVE
  The objective of this study was to investigate MDM2 (murine double minute 2) protein expression and evaluate its relationship with some anatomical and pathological aspects, aiming also to identify prognostic factors concerning local recurrence-free survival, metastasis-free survival and overall survival in patients with primary liposarcomas of the extremities.
  
  
  METHODS
  Of 50 patients with primary liposarcomas of the extremities admitted to a Reference Service, between 1968 and 2004, 25 were enrolled in the study, following eligibility and exclusion criteria.
  
  
  RESULTS
  The adverse factors that influenced the risk for local recurrence in the univariant analysis included male sex (P = 0.023), pleomorphic histological subtype (P = 0.027), and high histological grade (P = 0.007). Concerning metastasis-free survival, age less than 50 years (P = 0.040), male sex (P = 0.040), pleomorphic subtype (P < 0.001), and high histological grade (P = 0.003) had a worse prognosis. Adverse factors for overall survival were age under 50 years (P = 0.040), male sex (P = 0.040), pleomorphic subtype (P < 0.001), and high histological grade (P = 0.003).
  
  
  CONCLUSIONS
  There was no correlation between immunohistochemically observed MDM2 protein expressions and the anatomical and pathological variables studied. The immunohistochemical expression of MDM2 protein was not considered to have a prognostic value for any of the surviving patients in this study (local recurrence-free survival, metastasis-free survival, or overall survival). The immunoexpression of MDM2 protein was a frequent event in the different subtypes of liposarcomas.
authors.affiliation: Institute of Orthopedics and Traumatology, HC, Medical School, São Paulo University, São Paulo, SP, Brazil. zosimo_jr@yahoo.com.br
authors.forename: Rosalvo Zósimo
authors.initials: RZ
authors.lastname: Bispo Júnior
authors.forename: Olavo Pires de
authors.initials: OP
authors.lastname: Camargo
authors.forename: Cláudia Regina G C M de
authors.initials: CR
authors.lastname: Oliveira
authors.forename: Renée Zon
authors.initials: RZ
authors.lastname: Filippi
authors.forename: André Mathias
authors.initials: AM
authors.lastname: Baptista
authors.forename: Marcelo Tadeu
authors.initials: MT
authors.lastname: Caiero
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism*; D001706:Biopsy; D018572:Disease-Free Survival; D005121:Extremities; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D008080:Liposarcoma / Q000378:metabolism* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000378:metabolism / Q000401:mortality; D051736:Proto-Oncogene Proteins c-mdm2 / Q000378:metabolism*; D012737:Sex Factors; D012983:Soft Tissue Neoplasms / Q000378:metabolism* / Q000401:mortality; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2